Dr John Bridgewater

Dr John Bridgewater

MRCP, PhD

Consultant Medical Oncologist

I am a Clinical Researcher at the UCL Cancer Institute. I trained in medicine at Oxford and University College London, and specialised in Medical Oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals. I hold a PhD in gene therapy from the Institute of Cancer Research. I lead the National Cancer Research Institute subgroup in hepatobiliary malignancy, and have a laboratory programme at the UCL Cancer Institute investigating carcinoma of unknown primary origin. I have participated in a number of landmark studies in GI malignancy and I was senior author on the seminal publication in advanced biliary tract cancer, the ABC-02 study. I am chief and co-chief investigator on 3 lead studies in the NCRI upper GI portfolio and serve on a number of committees including those for the NCRI (UGI and colorectal), CTAAC and NICE.

I am a chief investigator for the ABC-04 study, a phase 1b study of AZD6244 or Selumitinib with Cisplatin and Gemcitabine in biliary tract cancer. This is a lead component of the NCRI hepatobiliary portfolio which I lead and coordinate. I have developed an international collaboration of biliary tract investigators the collaboration with whom is essential for future studies. I am also co-chief investigator for the BILCAP (adjuvant treatment in biliary tract cancer), EPOC-B and New EPOC (neoadjuvant treatment for colorectal liver metastases). In addition I am on the trial management groups of the SCOPE (chemoradiation in oesophagogastric cancer), SCALOP (chemoradiation in pancreatic cancer), and the biliary tract portfolio. I direct the translational programmes for these studies through multiple collaborations in progress. The blood and tissue banks developed represent a unique resource of material in the context of patients in clinical trials run to GCP standard. I continue to contribute to the NCRI GI portfolio and am consistently the highest recruiter into a number of studies.

I lead a laboratory and clinical programme in carcinoma of unknown primary (CUP). The central hypothesis is the value of molecular diagnosis for CUP both in laboratory and clinical practice. This work has involved the investigation of mRNA, microRNA and methylation signatures and a clinical trial to determine the utility of molecular diagnosis. This works is part of collaborations completed and continuing with Agendia, Manuel Esteller and Rosetta Genomics. I also leads the clinical service in the Integrated London Cancer Consortium.

NHS Trust

  • University College Hospital London NHS Trust.

LOC 95 Harley Street
HCA UK at University College Hospital